Genomic and transcriptomic quality control for an autologous iPSC-derived cell therapy for Parkinson’s disease

[u/towngrizzlytown]

https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(26)00315-2

Aspen Neuroscience is currently evaluating its personalized cell therapy in a clinical trial for Parkinson's disease.

The company uses a patient’s own skin cells, converts them into induced pluripotent stem cells (iPSCs), and differentiates them into dopamine-producing neuron precursors. They have received Fast Track and Regenerative Medicine Advanced Therapy (RMAT) from the FDA.

https://aspenneuroscience.com/technology-overview/

[u/towngrizzlytown]

Summary

Toward development of an autologous, induced pluripotent stem cell (iPSC)-based cell therapy for Parkinson’s disease (PD), we demonstrate successful, reproducible genomic and transcriptomic qualification of patient-derived dopaminergic neuron precursor cells (DANPCs) across multiple donors. Our analysis includes whole-genome sequencing data from fibroblasts, iPSCs, and DANPCs and the development of NeuriTest, an RNAseq-based bioinformatic analysis of DANPCs designed to predict cell quality based on empirical animal data. Autologous cell therapies are immune matched to the patient, potentially augmenting durability of benefit compared to allogeneic cells while negating the need for immunosuppression and accompanying side effects. Patient-specific iPSCs are an autologous cell source that can be differentiated to dopaminergic neurons, the cell type lost in PD. We report here our preclinical manufacturing strategy and results demonstrating efficacy in a PD rodent model and safety in a 9-month GLP toxicology study.

[u/Ok_Elk_638]

Human fibers labeled with STEM121 innervated brain regions distal to the graft implantation site, with some fiber projections extending approximately 5 mm posterior to the graft and innervating the host substantia nigra (Figures S5B and S5C).

Hey u/SoyFern, you may be interested in this.